Bone Marrow Transplantation News

Survival appeared comparable among patients with lymphoma whether they underwent hematopoietic stem cell transplantation with a haploidentical related donor or matched sibling donor, according to the results of a retrospective study.

Patients with acute myeloid leukemia who underwent autologous stem cell transplantation with curative intent remained at risk for late leukemia recurrence, according to retrospective study results.

Lifestyle choices can contribute considerably to a person’s cancer risk, as well the outcomes they achieve after they are diagnosed with a malignancy.

The use of thalidomide, bortezomib and dexamethasone may improve response rates compared with cyclophosphamide, bortezomib and dexamethasone prior to autologous stem cell transplantation for multiple myeloma, according to results of a randomized, open-label phase 3 trial.

The FDA granted ruxolitinib breakthrough therapy designation for the treatment of patients with acute graft-versus-host disease.

CHICAGO — Candace Johnson, PhD, president and CEO of Roswell Park Cancer Institute, discusses how research in immunotherapy and genomics can lead to tailored personalized treatments at the ASCO Annual Meeting.

CHICAGO — Dawn L. Hershman, MD, MS, associate professor of medicine at Columbia University Medical Center, reviews study results that identified comorbidities and lifestyle-related factors that can predict chemotherapy-induced peripheral neuropathy risk at the ASCO Annual Meeting.

Employees of SLACK Incorporated — publisher of HemOnc Today — wore white today in support of White Out Cancer Day.

Coffee no longer should be classified as carcinogenic to humans, according to a working group from WHO’s International Agency for Research on Cancer.

This year’s ASCO Annual Meeting featured the theme “Collective wisdom: The future of patient-centered care and research.”